Targeted Therapeutics for Solid-Tumor Cancer

First-in-class inhibitors of a novel onco-channel

Learn More Oncology Programs

We are developing cancer drug candidates that target and inhibit the function of TRPV6

TRPV6 is a selective calcium channel present in high amounts on the surface of cancer solid-tumor cells and required for the growth, metastasis and resistance to programmed death.

Invest Icon

Invest

We are a private oncology-focused company developing a new class of targeted cancer treatments. If you are an accredited investor and would like to learn about current investment opportunities please contact us.

More Info

Partner Icon

Partner with us

We are seeking development and commercialization partners for SOR-C13. We are also seeking partnerships / research collaborations for our peptide-drug conjugate platform.

Contact Us

Science Icon

Our Science

Our discovery of the toxin in the saliva of the venomous short-tailed shrew has led to the creation and continued development of a new class of targeted cancer treatments.

Learn More

Phase 1 Complete

Oncology Development Programs

SOR-C13 is a first-in-class peptide in development for the targeted treatment of cancer. A multi-center Phase 1 clinical trial is complete. The next clinical trials are planned for early 2018.

We are also developing small peptide-drug conjugates that deliver potent cancer-killing payloads directly to tumors.

SOR-C13 Peptide-Drug Conjugate

Latest News & Events

AACR Annual Meeting
Soricimed will present at the 2018 AACR annual meeting.
Biotech Showcase 2018, San Francisco CA
Biotech Showcase™ is an investor and networking conference devoted biotechnology and life sciences companies.
Soricimed featured in BioTuesdays
Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer.

Sign up to receive updates from Soricimed

Powered by Innovasium